Karyopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Beats Expectations By $0.02 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) posted its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02, Zacks reports. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.

Karyopharm Therapeutics Trading Up 2.2 %

NASDAQ KPTI opened at $0.63 on Wednesday. Karyopharm Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.70. The firm has a 50 day moving average of $0.67 and a two-hundred day moving average of $0.76.

Analyst Ratings Changes

Several research firms have weighed in on KPTI. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Monday, February 10th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Piper Sandler boosted their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).